Rahul Mahajan, Hitaishi Mehta, Dipankar De, Sanjeev Handa
{"title":"Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients.","authors":"Rahul Mahajan, Hitaishi Mehta, Dipankar De, Sanjeev Handa","doi":"10.1111/pde.15882","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oral tofacitinib shows promise for pediatric alopecia areata (AA), but more data on its efficacy and safety are needed.</p><p><strong>Methods: </strong>We analyzed 36 patients aged ≤ 16 years with moderate to severe AA (SALT score > 20) who received at least 6 months of oral tofacitinib.</p><p><strong>Results: </strong>SALT75 was achieved in 72.2% (26/36) and SALT100 in 52.8% (19/36) within 4.1 ± 1.7 and 6.7 ± 2.8 months, respectively; 27.8% (10/36) were non-responders. Nine patients had adverse events, with two requiring treatment discontinuation.</p><p><strong>Conclusion: </strong>Tofacitinib is effective for pediatric AA, with rapid regrowth in responders. The durability of benefit and need for long term maintenance therapy require further investigation.</p>","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pde.15882","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Oral tofacitinib shows promise for pediatric alopecia areata (AA), but more data on its efficacy and safety are needed.
Methods: We analyzed 36 patients aged ≤ 16 years with moderate to severe AA (SALT score > 20) who received at least 6 months of oral tofacitinib.
Results: SALT75 was achieved in 72.2% (26/36) and SALT100 in 52.8% (19/36) within 4.1 ± 1.7 and 6.7 ± 2.8 months, respectively; 27.8% (10/36) were non-responders. Nine patients had adverse events, with two requiring treatment discontinuation.
Conclusion: Tofacitinib is effective for pediatric AA, with rapid regrowth in responders. The durability of benefit and need for long term maintenance therapy require further investigation.
期刊介绍：
Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
